IN 1951
Nilsson I revolutionized the treatment of drug overdosage by introducing supportive therapy and thereby reduced mortality from 25 per cent to 2 per cent.
Since that time, our attention has been directed towards eliminating the drug as rapidly as possible, since length of coma bears a close relationship to complication rate, the most common of which is respiratory tract infection.
Diuresis 2 and dialysis a are eflqcient methods of eliminating water soluble drugs from the circulation. Adsorption techniques are also effective measures. 4, 5 There remains, however, a problem group of drugs which are strongly lipophilic -Ethchlorvynol, Glutethimide, Methyprylon and Methaqualone. These drugs produce lengthy coma and by their physical nature are poorly water soluble and therefore do not respond well to measures which rely on aqueous solution. ~-s In fact, forced diuresis is contraindicated because not only does one see obvious signs of oedema in the conjunctivae, skin and lungs but cerebral oedema also occurs and will serve to further confuse the neurological picture. In one case of Ethchlorvynol poisoning we saw bilateral retinal detachments. At this time there is no satisfactory explanation for the mechanism of this oedema.
Castor oil has been used to gavage patients with lipophilic drug overdosage and anecdotal reports have been favourable. Nurses report messy beds for a shorter time! Bowel sounds disappear in deep coma and it is suggested that unabsorbed drug may remain in the gastro-intestinal tract at this time. 9 Castor oil may act as a ligand as well as a cathartic and prevent unabsorbed drug from leaving the gastro-intestinal tract.
In an attempt to substantiate these possibilities, patients with lipophilie drug overdosage were given approximately 500 ml castor oil by nasogastric tube every twelve hours during coma in addition to the appropriate supportive therapy. The response to this treatment was not one of overwhelming enthusiasm by the nursing staff until they were convinced that patients woke up sooner. The response of the medical staff varied from mild disdain to abject horror.
Therefore an experinaental study was undertaken to confirm that castor oil acts as a ligand and also that its use reduces coma time in Ethchlorvynol poisoning. Ethchlorvynol/kg body weight both plain and in castor oil solution, the dose of castor oil being 10 ml/kg. This was done in crossover fashion so that each dog became its own control. These dogs were treated as we treat patients with drug overdosage in the Intensive Care Unit and when appropriately in coma were intubated and artificially ventilated until such time as they no longer tolerated the tracheal tube. They also had appropriate intravenous therapy. The observed fall in body temperature was obtunded by infi'ared heat lamps. The appropriate cuff drill and tracheobronchia] toilet were carried out and position was changed two-hourly. Serial serum concentrations were obtained by the method described by Frings and Cohen. 1~ The results are shown in Figure 1 .
Experiment 2 was designed to more closely mimic the clinical situation, in that castor oil was given at the same relative point in time of coma as it would be administered to a patient.
Ten crossover experiments were performed with the Ethchlorvynol dose in- creased to 300 mg/kg in order to extend the coma time and the castor oil dose increased to 15 ml/kg. Serial blood estimations were repeated as before and plotted in the same way. The results are shown in Figure 2 .
DISCUSSION
The important points in Figure 1 are, first, that peak serum levels were reduced where the castor oil solution was employed but they occurred at approximately the same time and this suggests a ligand effect. Second, that the slopes of decay differ in that the half-life for Ethchlorvynol is 14 hours and for the castor oil solution is 10 hours. The clinical significance of this is doubtful.
The curves in Figure 2 do not show a ligand effect but do show a significant decrease in drug half-life of the same general order as the first set of figures. The drug half-life at different dose levels should not change as long as a single inactivating mechanism operates. The fact that we find here a lengthening of the half-life in the serum with increasing dosage, suggests that Ethchlorvynol is inactivated by an easily saturated, rapidly acting mechanism and also by a slower mechanism that has a much greater capacity. It would appear that the effective dose level in the first experiment is reduced by the ligand effect of castor oil.
The second experiment, on the other hand, shows identical intercepts and identical peak levels and some additional explanation for reduction in half-life is required. The data suggests the possibility that castor oil in this case increases the effective distribution space and that Ethchlorvynol may well diffuse from the circulation into the castor oil in the bowel lumen. We are presently investigating this hypothesis.
CLINICAL OBSERVATION
A retrospective study was done to compare the course of two groups of five patients each who had ingested an overdose of a lipophilic drug and had been treated similarly except for the addition of castor oil to the treatment regimen. The results are shown in Figure 3 .
The results shown in Figure 3 , which deal with Methyprylon overdose, indicate that castor oil treatment of patients is even more effective than the dog studies done in Figure 2 would indicate. The shortening of coma time is clinically highly significant. We therefore recommend the use of castor oil in cases of lipophilic drug overdose in view of the foregoing.
CANADIAN ANAESTHETISTS' SOCIETY ~OURNAL S UIVflViARY
A clinical trial of castor oil in overdoses of lipophilic drugs gave a strong clinical impression that it was effective in speeding up recovery. Therefore, animal experiments were undertaken to confirm that castor oil acts as a ligand in Ethchlorvynol poisoning and that its use reduces coma time.
Serial serum levels of Ethchlorvynol were obtained from dogs given Ethchlorvynol 150 mg/kg alone, and the same dose dissolved in castor oil 15 ml/kg in a crossover fashion. The result was a reduction of peak serum levels and of the halflife of the drug when the castor oil solution was used.
In order to mimic the clinical situation more closely, a further crossover study was undertaken using Ethchlorvynol 300 mg/kg alone and the same dose followed by castor oil 15 ml/kg repeated q12h. This showed no delay in reaching peak serum concentration and no reduction of peak levels. However, it did show a 31 per cent reduction in the half-life of the drug. This change is statistically significant, and supports the continued use of castor oil in lipophilic drug overdose.
R~StrM~
Un essai clinique de l'huile de castor dans le traitement des intoxications par surdoses d'agents lipophiliques avait laiss6 l'impression que cet agent abr6geait le temps de r~cupdration. Ceci nous a amen~ ' faire l'essai de cet agent chez l'animal afin d'~valuer sa capacit6 ~ lier rEthchlorvynol pour ainsi raccourcir la dur6e du coma.
L'on a obtenu par prdl6vements sdrids les taux sdriques d'Ethchlorvynol chez des chiens ayant re~u cet agent ~t la dose de 150 mg/kg lors d'une premiere expdrience et, dans un deuxi~me temps, la m~me dose dissoute dans rhuile de castor A raison de 10 ml/kg. Les taux s~riques maxima ont 6td plus petits chez les chiens ayant regtt l'huile de castor; la demivle de l'Ethchlorvyno] a 6t6 plus courte ~gale-ment dans le deuxi6me groupe.
Dans le but de simuler davantage les situations cliniques, une seconde sdrie d'expdriences a dtd entreprise, utilisant cette lois rEthchlorvynol ~ une dose de 300 mg/kg avec r6pdtition aux 19. heures de la m~me dose suivie d'huile de castor la dose de 15 ml/kg. On n'a pas observ6 dans ces cas de retard ~t atteindre les taux sdriques maxima et ces m~mes maxima n'ont pas dt~ rdduits. Cependant, on a trouv6 une r6duction de 31 pour cent de la demi-vie de rEthchlorvynol. Ce rdsultat statistiquement significatif confirme l'utilitd de rhuile de castor dans le traitement de la surdose en agents lipophiliques.
